Zantac Lawsuit


Researching drug company and regulatory malfeasance for over 16 years
Humanist, humorist
Showing posts with label Discontinuation Nonsense. Show all posts
Showing posts with label Discontinuation Nonsense. Show all posts

Sunday, November 06, 2011

GlaxoSmithKline - The "Maladaptive" Company



There are many people/organisations that I greatly admire for their part in creating awareness in this minefield of deceit and fraud associated with the Seroxat scandal. Bloggers that have stood the test of time, Seroxat Secrets and GSK Licence To Kill have been at the forefront of spreading awareness about the dangers of Seroxat and the less than honest approach of it's manufacturer, GlaxoSmithKline.

Then we have support groups such as The Seroxat User Group, whose owner hasn't even taken Seroxat but sees there is a huge problem and has striven to help expose that problem through her advocacy work.

There's also been people like Alison Bass, Evelyn Pringle, Shelley Jofre, three journalists who have put their careers on the line, all of whom have, at one time or another, exposed the failings of GlaxoSmithKline and the regulatory systems, namely the MHRA and the FDA.

I've great admiration for the parents of both Sharise Gatchell and Sara Carlin, two teen who both took their own lives after being prescribed Seroxat. The strength of their parents to expose that dangers of Seroxat has given me strength over the years I have known them.

Charles Medawar for his tireless work in showing how the MHRA showed utter contempt for Seroxat Sufferers also deserves a mention, as do Prof David Healy, Peter Breggin and Joseph Glenmullen.

Attorney's in the US whom have shown dogged determination to get to the truth include The Tracy Law Firm, Donald J. Farber, Baum, Hedlund, Aristei & Goldman

There are many more, some I've met in person, others I hope to meet someday.

One such person is Rob Robinson, an activist who, with balls of steel, took the fight right to the doorstep of GlaxoSmithKline. If there was any justice in this world Rob, along with the aforementioned would be commended by their respective governments for exposing the dirty deeds of the UK's biggest pharmaceutical company.

The author of the Seroxat Secrets website recently posted about the recent $3 billion fine imposed on GlaxoSmithKline, the biggest fine in history to settle United States government civil and criminal investigations into its sales practices for numerous drugs. Seroxat Secrets wrote:


$3 billion – yes that’s record – but still no prison time.

It strikes me there are a couple of points coming out of this story:

1 – it seems if you have enough money you can buy your way out of trouble… even if that ‘trouble’ is criminal.

2 – Andrew Witty thinks he’s changed Glaxo – he said “…This is a significant step toward resolving difficult, long-standing matters which do not reflect the company that we are today…”

Well Andrew, this deal is in the US – what about the UK?

You’re not quite so happy for the new, improved GlaxoSmithKline to settle claims in the UK are you, now Andrew.

Could it be because you know the UK legal system works in your favour, so you can effectively ignore UK cases… in the UK cases like this are not heard in front of a jury, but in front of a high court judge – and funding is not easy to get. Basically in the UK we have no real chance to take on big business and patients not protected by the MHRA.

He is absolutely correct.

His post prompted me to browse through the archives of the Paxil Protest website, a site created by Rob Robinson, a site that was a minefield of information, a site that GlaxoSmithKline wanted shut down. One does not have to be a highly paid lawyer to see why they wanted it removed.

I've been writing about the MHRA, GlaxoSmithKline and Seroxat for 6 years. If I continued to write for a further 20 years I wouldn't come anywhere near what Robinson achieved. The man is a legend.

The following shows how effective Robinson was. It ends with a quote from Karen Barth-Menzies, yet another hero/heroine of mine. This is especially for Addleshaw Goddard, GlaxoSmithKline's UK law team.


Paxil Addiction



....there have been a number of systematic studies in humans looking at the potential for Paxil for abuse, tolerance and physical dependence. So actually, there is data to date to negate the statement that it has not been systematically studied, because, in fact, it has been.— Sworn testimony of Dr. David WheadonSenior Vice President, GlaxoSmithKline Regulatory Affairs and Product Professional Services (10/19/2000)

DRUG ABUSE AND DEPENDENCE

Controlled Substance Class: Paxil is not a controlled substance. Physical and Psychologic Dependence: Paxil has not been systematically studied in animals or humans for its potential for abuse, tolerance or physical dependence. While the clinical trials did not reveal any tendency for any drug-seeking behavior, these observations were not systematic and it is not possible to predict on the basis of this limited experience the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, patients should be evaluated carefully for history of drug abuse, and such patients should be observed closely for signs of misuse or abuse of Paxil (e.g., development of tolerance, incrementations of dose, drug-seeking behavior).— Paxil June, 2005 Prescribing Information

Disregard for the moment that perjured testimony, and the studies that were never done (or ever will be): Any man, woman, or child, who has crawled through the "Hell beyond Hells" that is a severe Paxil withdrawal will tell you (assuming they lived) that, yes, he or she was dependent on the drug; a prisoner, if you will, for the simple reason that continuing to take Paxil staved off horrifying, debilitating and protracted withdrawal symptoms.

It is INSANE that I and others have had to stumble into and through this hell ... and then try to figure out how to get out of it basically on our own! Its like being thrown into a chemical version of Dante’s Inferno with no map showing you how to get out — or even if you can get out at all! I think (but don’t hope) I’m close to clawing my way out, but who knows? I hate to say it, but the thought just drifted into my head: All ye who enter here abandon all hope.— Journal entry, day #89 from a Paxil withdrawal diary kept by Rob Robinson, a Paxil survivor.

In the mind of a lay person this inability to quit Paxil qualifies as "addiction" regardless of whether a Paxil user craved the drug to "get high," like a "real" addict craves, for example, heroin.

How GlaxoSmithKline has dealt with the issue of Paxil dependency (i.e. addiction) mirrors efforts it undertook regarding the issue of Paxil withdrawal. GSK flatly denies that Paxil can cause dependency or addiction and, in fact, the company has gone to extraordinary lengths to keep the label of dependency or addiction from being associated with the use of Paxil.

The truth is GSK knows Paxil can, sans studies, cause physical dependency in significant numbers of people. That is absolutely the case. It is one of the principal reasons why GlaxoSmithKline has, for years, instructed its sales reps to, whenever possible, substitute the word "discontinuation" for "withdrawal" in communications with healthcare professionals — because withdrawal implies dependency. And dependency, quite naturally, suggests addiction.

Yet the volume of anecdotal information available to GlaxoSmithKline and the world — proving Paxil can, and does, cause dependency — is widespread, dramatic, compelling and overwhelming.

Charles Medawar, of Social Audit framed the issue perfectly when he wrote:

“There is obviously some confusion about the concept of dependence ... The simplest definition of drug dependence given by W.H.O. (the World Health Organization) is ‘a need for repeated doses of the drug to feel good or to avoid feeling bad’ (W.H.O., Lexicon of alcohol and drug terms, 1994). When the patient needs to take repeated doses of the drug to avoid bad feelings caused by withdrawal reactions, the person is dependent on the drug. Those who have difficulty coming off the drug even with the help of tapered discontinuation should be regarded as dependent, unless a relapse into depression is the reason for their inability to stop the antidepressant medication.”


Thanks to Mr. Medawar’s relentless efforts to expose the truth about Paxil (Seroxat in the U.K.) GlaxoSmithKline was forced to remove from its U.K. Patient Information Leaflet the following language:

“These tablets are not addictive” and “remember that you cannot become addicted to Seroxat,” and further that the withdrawal symptoms some people experience when stopping Seroxat “are not common and (they) are not a sign of addiction.”

Shattering GlaxoSmithKline's DSM IV "No Dependency" Shield

For now forget the studies GlaxoSmithKline refers to in Paxil's prescribing information mentioned above; those studies will never be performed for the simple reason they would provide conclusive evidence that use of Paxil can induce dependency. Evidence which would present an insurmountable threat to the fortunes of GlaxoSmithKline.

Today, the GlaxoSmithKline public act which claims Paxil cannot induce dependency — based on the latest version of the Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR (a.k.a. the DSM IV) — would play well if this were the "Theater of the Absurd." But not out here in the real world where lives are being shattered and people are dying because of Paxil.

The GSK dodge seeks refuge under cover of language which changed when the DSM III was supplanted by the DSM IV in which, according to Charles Medawar of Social Audit "the new definition of dependence specified that the presence of withdrawal symptoms — in the absence of at least two distinctive features of a drug problem — was not "dependence" at all. At a stroke therapeutic dependence ... officially ceased to exist. Once again, the problem revolved around the true meaning of "dependence" but, this time, the new definition both radically changed the meaning and defied common sense. To compound the problem the authorities then failed to explain, or even acknowledge, that this enormous shift in meaning had taken place.

The Pharmas zealously promoted the new definition, but the medical establishment welcomed it too — because it characterized "dependence" as something that no competent doctor would ever cause. As if by law, and at a stroke, "dependence" had again come to mean something like frank drug abuse. In line with tradition, dependency problems were pinned on users once again.

Internationally, the risk of New Dependence was considered so small, that the regulators never requested the SSRI Pharmas test their drugs.

For the sake of argument let's have the public give GlaxoSmithKline the benefit of the doubt, even though it's unwarranted. We can "test" GSK's specious DSM IV claim by parsing the manual's criteria for substance dependency on a point-bypoint basis

Remember, only three of the following criteria must be meet within a 12-month period for a diagnosis of substance dependency.

The Diagnostic and Statistic Manual (DSM IV), defines addiction (which it refers to as “substance dependence”) as follows:

A maladaptive* pattern of substance use, leading to clinically significant impairment or distress, as manifested by three (or more) of the following, occurring at any time in the same 12-month period:

(1) Tolerance, as defined by either of the following:

a. A need for markedly increased amounts of the substance to achieve intoxication or desired effect.

Many Paxil users must take larger doses of the drug over time as the efficacy of the drug wears off in order to achieve the desired effect.


b. Markedly diminished effect with continued use of the same amount of the substance.

Many Paxil users experience "SSRI poop out" (see D.J. Rapport, J. R. Calabrese, Tolerance to fluoxetine. J Clin Psychopharmacol 1993 Oct, 13 (5), 361.) after taking a fixed dose of the drug for a number of years. As a result they must increase their dosage in an attempt to regain efficacy. Even then, the increase in dosage sometimes has no effect.


(2) Withdrawal, as manifested by either of the following:

a. The characteristic withdrawal syndrome for the substance.

The phenomenon of Paxil withdrawal is an established fact now, and one acknowledged in the manufacturer's current drug labeling.


b. The same (or a closely related) substance is taken to relieve or avoid withdrawal symptoms.

Individuals trying to quit Paxil sometimes switch to another "SSRI" with a longer half-life (i.e. Prozac) in a attempt to simultaneously get off the drug and ameliorate its oftentimes severe withdrawal symptoms. (Like heroin addicts who use methadone.)


(3) The substance is often taken in larger amounts or over a longer period than was intended (loss of control).

Many individuals continue taking Paxil — long after they would like to stop taking the drug — to stave off extremely severe, debilitating and prolonged withdrawal symptoms that sometimes occur when stopping Paxil.


(4) There is a persistent desire or unsuccessful efforts to cut down or control substance use (loss of control).

"Same comment as for #3." Many individuals continue taking Paxil — long after they would like to stop taking the drug — because of the withdrawal symptoms that occur when stopping Paxil.


(5) A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects (preoccupation).

If Paxil was illegal many users would spend whatever time was necessary to get the drug "on the street," thus engaging in the same behaviors "real" addicts exhibit in their quest to obtain the drug they are dependent upon. A Paxil addict doesn't have to go this route since the doctor who (unwittingly) prescribed Paxil to him or her hands out refill prescriptions; all that's necessary to get more Paxil is a trip to the local pharmacy.


(6) Important social, occupational, or recreational activities are given up or reduced because of substance use (continuation despite adverse consequences)

(7) The substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance. (adverse consequences)

This is the situation lived out on a daily basis for thousands of Paxil dependents who have (quite often) discovered through the Internet why it is they are unable to quit the drug without experiencing disabling withdrawal symptoms.


Paxil and proof of dependency: In basketball it's what they call "a slam dunk."

In legal documents GlaxoSmithKline appears to make much out of the word "maladaptive" as used in the DSM pre-qualifier. In this context an acceptable medical synonym for the word "maladaptive" is "dysfunctional." If Paxil dependency is not a state of dysfunction (i.e. maladaptation) then the condition doesn't exist.

Based on what the world knows about Paxil today: Paxil should be — if not summarily banned — then at a minimum classified as a "Schedule II" drug by the United States Drug Enforcement Agency. (At the same time the DEA should change its scheduling guidelines under "(C)" to read "use of" vs. "abuse of" since that language lags behind today's realities.)

Rob Robinson - Paxil Protest

"We have been trying for years to raise public awareness about these issues because we have seen, through our litigation, the secret internal company documents that no one ever gets to see, not even the FDA. Even now, we are prohibited, due to confidentiality orders, from disclosing these documents. But, you can only hide the truth for so long. Too many people have been harmed by these drugs, too many lives have been shattered." - Karen Barth-Menzies - Paxil plaintiffs' attorney







Saturday, June 25, 2011

Are You Struggling With Seroxat/Paxil Withdrawal?



Are you struggling with Seroxat withdrawal? Have you tried desperately to wean yourself off but find yourself addicted? Have you asked your doctor for a safe, proven tapering regime?

Never fear, GlaxoSmithKline, the manufacturers of the drug you are desperately trying to wean off, should be able to help you.

Contact them and let them know you are addicted to their drug and you are struggling to wean off it. Tell them your doctor cannot help you as there is no available, proven protocol with regard to a safe taper.

Contact GSK Customer Relations via email at: customer.relations@gsk.com

If GlaxoSmithKline respond by telling you they cannot, under the Code of Practice of the Association of the British Pharmaceutical Industry [ABPI], offer you any personal advice regarding their product then please feel free to drop me a line.

Failing that, you could always contact the MHRA. They are the body that regulate the drugs you and I take. To date the MHRA have received 32,897 reported reactions to Seroxat and 10,563 Adverse reactions. 177 fatal adverse reactions have been reported to the MHRA.

If you seek help tapering off Seroxat and GlaxoSmithKline refuse to help you, drop the MHRA an email and ask them how you should taper from your Seroxat and, more importantly, how long it will take to be free from the withdrawal symptoms. Once again, if the MHRA quote the Code of Practice of the Association of the British Pharmaceutical Industry [ABPI] clause at you then please feel free to write me.

The MHRA can be contacted via email at info@mhra.gsi.gov.uk

Related article:

**EXCLUSIVE: Glaxo Turn Away Consumer Suffering Seroxat Withdrawal






Friday, June 24, 2011

How Glaxo Wanted to Turn the Issue of Withdrawal in Their Favour

One would think that a manufacturer of a product would act upon a defective product, particularly if that product was to be used by millions of people.

Glaxo launched Seroxat in direct competition to Eli Lilly's Prozac. Lilly, being Lilly, saw this as a threat. So battle did commence.

According to this recently surfaced internal file, GlaxoSmithKline [then SmithKline Beecham] knew of two studies that Lilly had carried out, those studies showed that Seroxat showed significantly higher rates of withdrawal problems when compared to Prozac.

How did GSK handle this?

Well, instead of addressing Lilly's findings they decided to play down the issue of Seroxat withdrawal. The fact that Seroxat withdrawal problems were significantly higher than Prozac saw Glaxo's team pull together the following plan.

Downloaded from DIDA Library

Downloaded from DIDA Library


You will note the date of the letter is July 1997, that's 14 years ago.

Let's catapult to present day, 2011, and an article I ran with on June 19.

GlaxoSmithKline UK had been contacted by a patient because she was at her wits end. She had, for some years, being struggling to withdraw from Seroxat. This was frustrating because she wanted to start a family and she knew the possible consequences of trying for a baby whilst hooked on Seroxat. Seroxat is a teratogen for those of you that don't know - The British drug regulator, the MHRA won't admit that it is though.

14 years on and, it appears, Glaxo still don't want to address the issue of Seroxat withdrawal. The woman who contacted them was told, not by Glaxo but by one of their lawyers, that Seroxat was not addictive and that she should "talk to her doctor."

The fact that this woman had already spoken with her doctor, who had no idea how to tell her to taper or how long it would take, seemed irrelevant to GlaxoSmithKline's lawyer!

"Zoe's" full story can be read HERE.


With Glaxo refusing to acknowledge those that suffer serious withdrawal problems at the hands of their product, we have a cluster of people who have been thrown onto the scrap heap. In a previously unseen BBC transcript [2002] from Panorama, Glaxo's Alastair Benbow told investigative journalist, Shelley Jofre, that Seroxat was not addictive, in fact he went one step further and said that people could stop taking Seroxat anytime they wanted, adding, "It is true that a proportion of patients may develop symptoms on stopping the drug. These are generally mild to moderate in nature."

It took me almost two years to quit Seroxat. For Benbow to suggest that my withdrawal was possibly mild to moderate in nature is seen as an insult. To suggest that "Zoe", the woman who featured in my June article, is possibly suffering only mild to moderate withdrawal also smacks of someone who has a characteristic of being conceited. Mine and "Zoe's" withdrawal are just two stories. Here's just a minuscule of other withdrawal comments left by people who have signed the Online Paxil Petition.

I've recently stopped taking Paxil after 18 months and have experienced many of the side effects associated with withdrawal - hot flashes, electrical "zaps", inability to concentrate, weight gain, dizziness, headaches, etc., etc., Had I been aware of these withdrawal horrors, I would have requested that my physician prescribe another medication.

I am going through hell trying to get off of this drug. I've been on it for 4 years - tried to get off of it twice, unsuccessfully, and am now trying a 3rd time. Each time I get so sick, I give in and start taking it again so that I can function. I never would have taken this drug if I would have known the consequences.

Very sick with electrical charges in head when trying to quite. This is like being addicted to hard core drugs. The manufacture needs to have a plan to withdraw people who take this. I have been sick for at least 2-3 days every time I try to decrease the dose. It's been a horrible experience. I want off this drug and no one seems to know how to stop it without getting sick.

There are more to read HERE, in fact over 10,000 more.

Glaxo's Alastair Benbow is aware of the voices on the Internet, in 2002 he had this to say to Shelley Jofre:

"...we cannot be driven by anecdote; we have to be driven by facts."

On being asked how long patients have to taper when coming off Seroxat, Benbow replied:

"That depends on the dose of Seroxat that the patient is on. In the majority of cases, if you are on one of the higher doses, it will only take a matter of weeks."

Maybe Benbow still remembers the 'plan' his employers set out in 1997 to basically debunk the withdrawal problems of Seroxat?

Fid

ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
US & CANADA HERE OR UK FROM CHIPMUNKA PUBLISHING

AUSTRALIAN ORDERS HERE 


Related article:

Previously Unseen Paxil GlaxoSmithKline Court Documents Part I







Friday, May 01, 2009

Dear Doctor... I'd like to show you something...

For those struggling with Seroxat/Paxil, you are probably faced with ignorance of doctor's and healthcare professionals as you describe your withdrawal problem to them. GSK Reps would have told them that the withdrawal lasts only maybe 2 weeks or so.

If you are frustrated that your Doc won't take you seriously or he drops your dose so drastically that you seem to be going out of your head with electrifying zaps [Known in the trade as 'dizziness'] - then print off the following and present it to your doctor.

A tapering protocol for all SSRi's may be available soon, it will only be a guide, but a guide is what is needed rather than the usual 'The patient must taper slowly' line that appears on patient information leaflets.

This from ehealthme.com regarding side effects and effectiveness of Seroxat/Paxil/Aropax (paroxetine hydrochloride) for females and males at all ages.

----

On Apr, 9, 2009: 62,164 related incidents are studied



**Notice the reductions in adverse reactions from 2004 onwards? This, I beleive, is a result of the public awareness created about Paxil/Seroxat both here in the UK and in America.

Overall results of Paxil:
Top drug interactions, adverse side effects of Paxil:



Bring a copy of this report to your health teams to ensure drug risks and benefits are fully discussed and understood.

For other SSRi's visit http://www.ehealthme.com/

Fid

ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING

Tuesday, February 10, 2009

Side effects and drug interactions analysis of Paxil Cr...

...for females aged 39-49

Interesting page from eHealthMe

Top drug interactions, adverse side effects:

1 Drug withdrawal syndrome 10,290 (16.82%)
2 Nausea 5,864 (9.58%)
3 Dizziness 4,733 (7.73%)
4 Anxiety 4,419 (7.22%)
5 Drug exposure during pregnancy 4,206 (6.87%)
6 Suicidal ideation 4,114 (6.72%)
7 Fatigue 3,882 (6.34%)
8 Drug ineffective 3,514 (5.74%)
9 Depression 3,511 (5.74%)
10 Headache 3,366 (5.50%)

Top co-used drugs:

1 Paroxetine Hcl 10,989
2 Vioxx 2,852
3 Xanax 2,541
4 Aspirin 2,533
5 Lipitor 2,065
6 Zyprexa 1,778
7 Synthroid 1,742
8 Neurontin 1,739
9 Ambien 1,651
10 Lasix 1,613

Recent 107 related drug checks on eHealthMe:

Vicodin, Paxil drug interactions (11 hours ago)

Paxil Cr (Glaxosmithkline) - EQ 25MG BASE side effects and drug interactions (14 hours ago)

Paxil (Glaxosmithkline) - EQ 20MG BASE, Bactrim Ds drug interactions (1 day ago)

Paroxetine Hydrochloride (Alphapharm) - EQ 10MG BASE side effects and drug interactions (4 days ago)

Lialda, Paroxetine Hydrochloride (Alphapharm) - EQ 10MG BASE drug interactions (4 days ago)

Paxil (Glaxosmithkline) - EQ 20MG BASE, Penicillin-vk (Teva) - EQ 500MG BASE drug interactions (4 days ago)

Finasteride, Paroxetine Hydrochloride drug interactions (5 days ago)

Paxil, Risperdal (Ortho Mcneil Janssen) - 0.5MG drug interactions (5 days ago)

Carbamazepine, Citalopram Hydrobromide (Actavis Elizabeth) - EQ 10MG BASE, Donepezil, Escitalopram (Alphapharm) - 20MG, Fluoxetine, Galantamine Hydrobromide, Ibuprofen, Namenda, Mirtazapine, Paroxetine Hydrochloride, Phenytoin, Seroquel, Zoloft, Warfarin Sodium drug interactions (6 days ago)

Depakote, Accutane (Hlr) - 40MG, Paxil (Glaxosmithkline) - EQ 20MG BASE drug interactions (1 week ago)

Paroxetine Hydrochloride side effects and drug interactions (1 week ago)

Loestrin 24 Fe, Paroxetine Hydrochloride drug interactions (1 week ago)

Paxil (Glaxosmithkline) - EQ 20MG BASE side effects and drug interactions (1 week ago)

Tricor (Abbott) - 145MG, Metoprolol Succinate (Kv Pharm) - EQ 50MG TARTRATE, Paroxetine Hydrochloride (Alphapharm) - EQ 20MG BASE drug interactions (2 weeks ago)

Paroxetine Hydrochloride side effects and drug interactions (2 weeks ago)

Acetaminophen, Aspirin And Caffeine, Plavix (Sanofi Aventis Us) - EQ 75MG BASE, Metoprolol Tartrate, Paroxetine Hydrochloride drug interactions (2 weeks ago)

Acetaminophen, Aspirin And Caffeine, Lipitor (Pfizer) - EQ 20MG BASE, Plavix, Metoprolol Tartrate, Paroxetine Hydrochloride drug interactions (2 weeks ago)

Plavix, Paroxetine Hydrochloride drug interactions (2 weeks ago)

Xanax (Pharmacia And Upjohn) - 2MG, Paxil (Glaxosmithkline) - EQ 20MG BASE, Chantix drug interactions (2 weeks ago)

Adderall 20, Paxil Cr drug interactions (2 weeks ago)

Xanax (Pharmacia And Upjohn) - 0.5MG, Invega (Janssen Lp) - 3MG, Paroxetine Hydrochloride (Alphapharm) - EQ 20MG BASE drug interactions (2 weeks ago)

Paxil side effects and drug interactions (2 weeks ago)

Paxil side effects and drug interactions (2 weeks ago)

Paxil side effects and drug interactions (2 weeks ago)

Clonazepam (Teva) - 0.5MG, Toprol-xl (Astrazeneca) - EQ 50MG TARTRATE, Paroxetine Hydrochloride (Apotex Inc) - EQ 10MG BASE/5ML drug interactions (2 weeks ago)

Tegretol, Nuvaring, Avalide (Sanofi Aventis Us) - 12.5MG;300MG, Paxil Cr (Glaxosmithkline) - EQ 25MG BASE drug interactions (2 weeks ago)

Paxil (Glaxosmithkline) - EQ 10MG BASE side effects and drug interactions (2 weeks ago)

Xanax (Pharmacia And Upjohn) - 0.5MG, Lipitor (Pfizer) - EQ 20MG BASE, Wellbutrin Sr (Glaxosmithkline) - 150MG, Prilosec (Astrazeneca) - 20MG, Paxil (Glaxosmithkline) - EQ 40MG BASE, Micardis (Boehringer Ingelheim) - 80MG drug interactions (2 weeks ago)

Naproxen, Paroxetine Hydrochloride drug interactions (2 weeks ago)

Nuvaring (Organon Usa Inc) - 0.015MG;0.12MG, Paxil (Glaxosmithkline) - EQ 20MG BASE drug interactions (2 weeks ago)

Adderall 30, Paxil Cr drug interactions (2 weeks ago)

Adderall 30, Paxil Cr (Glaxosmithkline) - EQ 25MG BASE drug interactions (2 weeks ago)

Xanax Xr (Pharmacia And Upjohn) - 1MG, Wellbutrin (Glaxosmithkline) - 100MG, Paxil (Glaxosmithkline) - EQ 10MG BASE drug interactions (2 weeks ago)

Propecia (Merck) - 1MG, Ativan (Biovail) - 1MG, Paxil (Glaxosmithkline) - EQ 20MG BASE drug interactions (2 weeks ago)

MANY MORE HERE



Fid


Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING

Wednesday, January 28, 2009

Study: Zoloft and Cipralex better than other drugs

Source: Forbes.Com


Doctors have long assumed that most antidepressants are interchangeable.

But according to a new study, Zoloft and Cipralex work slightly better than 10 other popular drugs, and should be psychiatrists' first choice for patients with moderate to severe depression.

Previous research found few differences between antidepressants. A U.S. government study in 2006 concluded that patients with major depression did equally well on different drugs.

But in a paper published online Thursday in the Lancet medical journal, two antidepressants came out on top, though only marginally.

International doctors examined more than 100 previous studies on a dozen antidepressants, which included nearly 26,000 patients from 1991 to 2007.

They found that Zoloft, developed by Pfizer Inc. and Cipralex, developed by Forest Laboratories in the U.S. and Danish drugmaker H. Lundbeck A/S in Europe, were the best options when considering benefits, side effects, and cost. In contrast, Pfizer's Edronax was the least effective.

All three drugs are now available generically.

The other drugs tested were Celexa, Cymbalta, Efexor, Ixel, Luvox, Prozac, Seroxat, Remeron, and Zyban



Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING

Sunday, January 18, 2009

SSRI chemical imbalance theory

The following is an extract taken from a featured article called 'The Media and the Chemical Imbalance Theory of Depression' by Jonathan Leo & Jeffrey R. Lacasse.

Abstract

The cause of mental disorders such as depression remains unknown. However, the idea that neurotransmitter imbalances cause depression is vigorously promoted by pharmaceutical companies and the psychiatric profession at large. We examine media reports referring to this chemical imbalance theory and ask reporters for evidence supporting their claims. We then report and critique the scientific papers and other confirming evidence offered in response to our questions. Responses were received from multiple sources, including practicing psychiatrists, clients, and a major pharmaceutical company. The evidence offered was not compelling, and several of the cited sources flatly stated that the proposed theory of serotonin imbalance was known to be incorrect. The media can play a positive role in mental health reporting by ensuring that the information reported is congruent with the peer-reviewed scientific literature.

Before you read the full article, take a look at the following:

Lexapro - Manufacturer - H. Lundbeck A/S - Denmark – (Forest Laboratories in the US) - "Lexapro corrects this chemical imbalance andmay help relieve the symptoms of depression" [Patient Information Leaflet]

Cipramil / Marketed under the Brand Name Celexa in the US - Manufacturer - H. Lundbeck / American partner Forest Laboratories: Google search "Celexa helps to restore the brain’s chemical balance by increasing the supply of a chemical messenger in the brain called serotonin."

Pristiq - Manufacturers - Wyeth: "As an SNRI, PRISTIQ affects the levels of two neurotransmitters thought to play a key role in depression — serotonin and norepinephrine. Serotonin and norepinephrine are chemicals that occur naturally in the brain. While no one knows for sure what causes depression, many experts believe that it may occur when neurotransmitters are out of balance." Pristiq website

Aropax [Seroxat] - Manufacturer - GlaxoSmithKline: "Aropax corrects the chemical imbalance and so helps relieve the symptoms of depression." GSK Australia

Geodon - Manufacturer - Pfizer: "How GEODON Works. Doctors believe GEODON helps balance certain natural chemicals in your brain. Balancing these chemicals helps treat your symptoms of acute manic or mixed episodes associated with bipolar disorder. And that can help you feel better." - Geodon Website

There are many more. Now read the article


Fid


Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING

An Interview with Joanna Moncrieff: The Myth of the Chemical Cure

Thanks to one of my readers, Ruth, for passing this on to me.

It's an interview with Joanna Moncrieff, author of the book, 'The Myth of the Chemical Cure: A Critique of Psychiatric Drug Treatment'

I shall re-publish the entire interview here for you all to read. The original page can be found here.

----

In this interview she responds to questions about this so – called "chemical imbalance" and the treatment of depression.

1) Dr. Moncrieff, first of all, what led you to write this about about "the myth of the chemical cure"?

What is written in textbooks about psychiatric drugs and how they work never seemed to match up to reality to me. So I started to look carefully at the research on drugs and gradually I came to realise that there was no evidence that they were acting specifically- that they were reversing the basis of a disease- as it was claimed. At the same time I was interested in how drugs came to be so highly regarded in psychiatry- how they came to be the dominant form of treatment. I realised that it was because they were believed to be specific that they were seen as so important, because the idea that they are specific underpins the idea that psychiatry is a medical activity, concerned with reversing medical diseases.

So I began to try and trace how the idea- the myth as I believed it - that they are specific treatments was constructed.

2) I would think that when people have to deal with the death of a mother/father, brother/sister, or even a pet, I think that it is natural and normal to feel depressed. When did we start giving anti-depressant medication for the normal transitions of life that we all have to endure?

The modern concept of depression, as a common condition in need of medical treatment, was invented and promoted in order to market the earliest antidepressants in the 1960s. However, it was when the market for benzodiazepines collapsed in the late 1990s that the pharmaceutical industry turned to depression to create a mass market.

It was during the 1990s that the idea that depression affects up to 1 in 4 of the population and other such figures were publicised and the motive was to create a market for the new and profitable antidepressants known as SSRIs.

3) How exactly do psychiatrists find out if there is a real chemical imbalance in the brain? Or are they just experimenting with patients?

Psychiatrists have no way of telling that someone has a chemical imbalance. The idea that depression is caused by a chemical imbalance is simply a hypothesis. There is no consistent evidence that there is any biochemical abnormality in people diagnosed as depressed. The idea has been promoted by drug companies and professional organisations, but the evidence base for it is almost non existent. Most experts say that the fact that people improve when you give them antidepressants is the strongest evidence that there is a chemical imbalance. But there are other ways of explaining this- antidepressants are psychoactive drugs, that may suppress emotional feelings, or just sedate people.

Anyway, as recent research shows, people improve barely more with antidepressant than they do with a placebo.

4) The number of pills for a wide variety of so- called " mental illnesses " seems to have skyrocketed. Someone is making a lot of money pushing these pills. Is it all about money?

Partly, but it is also about professional status. Psychiatrists push pills because it bolsters their position as doctors. Also governments have supported medical interventions like drugs because they look like simple solutions to otherwise complex and intractable problems. Also we live at a time when big business is very powerful, and governments are unwilling to reign it in.

5) I know there are some violent, aggressive, assaultive patients who either have to be physically restrained, or put in a special room, or a straight jacket. In such instances, are we simply sedating the patient or are we really treating them?

I think everyone would admit that at times like these we are simply sedating them, or using chemical restraint. What is more open to dispute is what we are doing to people whose behaviour is chronically antisocial, disturbing and maybe irrational. People like this are usually diagnosed as having chronic schizophrenia, or some other mental disorder. In this case, the drug treatment they are inevitably given on a long-term basis is dressed up as a treatment, but is often aimed at controlling their behaviour.

6) Are there germs, bacteria, viruses, and things that can be seen under a microscope that cause "mental illness"?

No- there are no proven physical causes of any mental illnesses.

7) We all have to deal with anxiety- we have to work, take tests, deal with disgruntled people- why do some people need anti-anxiety pills for the problems that we all have to face---and do these folks have some type of chemical imbalance?

Everyone is different and some people find stress harder to deal with than others.

This is partly due to upbringing and environment, but some of it is probably due to the variation in our biological makeup. However, I don't think it is something you can pinpoint, like a chemical imbalance.

It's just that we are all different, biologically as well as psychologically. You can't "correct" these differences (assuming you could identify them, which I don't think you will ever be able to do) without eradicating individuality itself.

8) Is there really such a disease as attention deficit disorder or is this just a bunch of symptoms that have been lumped together in some fashion?

Its not my specialist area, but child psychiatrists I know say that they can always find a better explanation for a child's behaviour than calling it ADHD. ADHD is a label that locates the problem in the individual child, whereas I suspect the problem really often lies in the family and the wider environment. The only reason for giving someone the label of ADHD, of course, is in order to justify giving the child stimulants. There is a big debate about whether these are useful- and if so whether they are worthwhile. They can make a child pay attention at first, but whether this is really beneficial is unclear. Also their effects probably wear off (like most drugs taken for long periods)- and the latest 3 year follow up of the biggest randomized trial of stimulants shows no benefits over non drug treatment at three years.

9) I have read some crazy stuff on the Internet about statins being given to 8 year old children. Is there any sane, reasonable, rational, realistic reason to give an 8 year old child a statin?

I don't know about the wisdom of giving children statins, but childhood obesity (not a nice word) is certainly an indication that there is something very wrong with our society. It is also caused of course by drugs like the new antipsychotics, which are being more commonly prescribed to children. So some childhood obesity is being caused by drugs in the first place.


10) Here in the United States, we once had a commercial that said " relief is just a swallow away". Have the pharmaceuticals taken this mass drugging way too far?

Everyone is looking for a magic bullet for everything nowadays. The pharmaceutical industry have certainly helped create this situation, but again I think it is the broader political climate that has encouraged this to happen. Popping pills to solve your problems is a perfect consumerist activity, and it helps keep people so worried that they don't have time to challenge the system. Accepting life's ups and downs is not a good recipe for keeping people working their guts out to buy more stuff.

11) I often see individuals who seem to have no coping skills, low frustration tolerance and a lack of thinking skills. Should not these people get training and counseling, rather than some pill for their alleged " chemical disorder"?

Yes, these would be better, but often there is no individual solution. We have to ask why some people get this way, and what changes we can make to society to prevent it happening and to help them when it does.

12) Are there any psychiatric diagnosis which in your mind, are true "chemical imbalances" for example chronic schizophrenia?

No. Organic conditions like dementia and learning disability have a physical basis (but not a simple chemical imbalance). For mental illnesses like schizophrenia, manic depression and others, no physical cause has ever been proven. It is often said that we have evidence that they are genetic- but this evidence is much weaker than presented (Jay Joseph gives a good deconstruction of this). It is said that people with schizophrenia have different shaped brains- but again the evidence is weak and inconsistent and drug induced effects have not been ruled out.

13) Do you have a web site where we can get more information?

The Critical Psychiatry Network has a website where there are many interesting papers posted and other information. The address is www.criticalpsychiatry.co.uk

14) What question have I neglected to ask?

Whatever mental illnesses consist of, and we do not know, but have no good evidence at present to think they are caused by specific brain diseases like real neurological conditions, when we treat them with drugs we are merely drugging people. This may suppress the symptoms, which may be helpful for a while, but obviously there are adverse consequences. If you are drugged you are usually slower and less emotionally sensitive than if you are not under the influence of drugs. Psychiatrists need to be more honest about this- but so do politicians and society as a whole. We are pretending to treat or cure people with mental illness because that makes us feel alright about controlling them. Sometimes we need to control them but we should at least be honest about what we are doing. Pharmaceutical companies are cashing in on our dishonesty.

Published August 7, 2008


Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING

Thursday, January 15, 2009

Concerned Canadian Citizen [Email to Health Canada]

I've just been copied in on an email sent to Health Canada from a very concerned Canadian citizen. They have given me permission to post the email on my blog. The person's name and email address have been redacted at their request:

Dear Health Canada,

It is very obvious that Paxil poses a serious threat to the life and liberty of children and adults in Canada. It seems equally as obvious that there is an overprescribing issue. Tonight I found a website created by GlaxoSmithKline. The sites intended purpose is pre-screening for shyness which they feel their drug is suited well for. I find that extremely difficult to believe. (Both the fact that shyness is a mental illness at all and that the benefits of Paxil would outweigh any risk)


I'm not going to sit here and try to convince you of Paxil's mounting death toll and the 16 yr wake of needless suffering. I know you know about it so let's not debate the obvious.


I did some research on the side effects of other known disasters you have pulled from the shelves such as Vioxx and Thalidomide. I am wondering why, in spite of the fact that SSRI drugs have a much higher number of reported severe side effects than either drug mentioned above; you have done very little about it.

I would suggest Paxil be removed from the shelves but someone is making far too much money for that request to be realistic.


1) When you are going to demand GlaxoSmithKline to make their warning labels more visible? I have seen the warning label and it does not stand out at all which was also reported on the evening news which focused on the senseless death of Sara Carlin and Ontario Chief Corners office. I don't think that this is an unreasonable request especially considering a more visible label could have saved some of the Canadian lives we have already lost and will save some in the future which should be Health Canada's main focus.

2) When can the public (Paxil addicts) expect a withdrawal program?

You, along with doctors have been made aware of how difficult it is to withdraw from Paxil. Leading experts suggest greater than 40% of users will experience severe withdrawal complications. This is hardly a number to ignore. I am also wondering how many people have been forced into poverty and live off of disability as a result of this health care disaster that is out of control and has been for many years.

After corresponding with world experts on SSRI withdrawal it is my understanding there is no withdrawal program in place and that you have never requested one in spite of how debilitating withdrawal can be and the threat to one's life. GlaxoSmithKline suggests a two week tapering period. Experts like Dr. David Healy have regarded this as nearly an impossible challenge for patients and a very dangerous one at that. After being prescribed Paxil for PMDD (bad PMS) and spending two years getting off these drugs, I can assure you that the experts are not exaggerating. I don't know how I survived it. A child with an uninformed doctor and ignorant parent or caregiver does not stand a chance. Don't reply to me and tell me that Paxil is not licensed for children. It is being prescribed off label every single day for children and we both know it.

Considering the number of people taking SSRI drugs I feel strongly that these issues should have been addressed carefully long before now. It seems to me that Health Canada has demanded the bare minimum from a company guilty of tax evasion and collusion in the United States, Half a billion dollars worth of bribery in Italy, Illegal drug trials in New Jersey, ghost writing, and faced criminal charges for knowingly promoting a drug proven ineffective and extremely dangerous in children. I'm sure I have missed a few but surely you get my point. With the latter in mind it has come as a shock to me and other consumer advocate groups that GSK is planning on a second attempt at a pediatric license in Japan.

If I were to pull any one of those stunts would you continue to do business with me and bend the rules in my favor or would I be behind bars? If I were your neighbor would you trust me to watch your child?

Of course you would not trust me with your child. But you have been telling Canadians to trust GSK with their children knowing the company is promoting an unsafe drug for our most vulnerable members of society and the very people that will be running this country one day.

GlaxoSmithKline has been selling life saving drugs for a very long time. However, this does not give them a license to intentionally deceive Health Canada, Canadian doctors and consumers.

It has always been your job to protect and defend the health and safety of Canadians. I feel that in regard to Paxil, you have failed us.

I would really like a reply to this but not a cut a paste of a standard reply. I intend to report on this as it will be the focus of a paper I have been working on.

Regards,

Name redacted



Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING

Thursday, December 18, 2008

Interview with Shelley Jofre

Here we have an Interview with Panorama investigative reporter, Shelley Jofre.

Shelley was instrumental in exposing GlaxoSmithKline and the MHRA plus fraudulant psychiatrists with her reports concerning Seroxat.




The first documentary, 'The Secrets of Seroxat' was aired in 2002 and saw 65,000 people ring the BBC helpline and they received over 1,500 emails. This prompted Shelley to make a follow-up programme called 'Emails from the Edge', which was broadcast on BBC TV on the 11th May 2003. 'Taken on Trust', her third investigation in to Seroxat, shook the foundations of the MHRA to the core as she exposed how they had failed the British public regarding thier ignorance and incompetence. Her fourth and final installment [thus far] of the whole Seroxat scandal was called 'Secrets of the Drug Trials', she showed how GlaxoSmithKline (GSK) attempted to show that Seroxat worked for depressed children despite failed clinical trials. This was aired in 2007.

On November the 1st, 2007, Shelley shed further light on her investigations into Seroxat when she was interviewed at Coventry University as part of the 'Coventry Conversations' series. The interview is available for download and is over an hour in length.

The interview with Shelley is a pretty amazing insight into how GlaxoSmithKline saw her as a major nuisance as she kept chipping away at them, digging for answers.

Shelley Jofre is a terrific reporter, a constant thorn in the side of GlaxoSmithKline and the MHRA. If there were any justice in this world then Shelley should recieve all the accolades. She put the dangers of Seroxat on the map here in the UK, she exposed the clandestine goings-on at the world's second largest pharmaceutical company and the body that regulate them, the MHRA.

A key point in these four documentaries was when she asked Head of European Psychiatry , for GlaxoSmithKline, Alistair Benbow, if Seroxat could be safe in children. His reply still baffles me to this day, he answered, "Absolutely. It could be. We haven't got a license in children yet..."

Quite why Benbow would suggest that Seroxat could be safe in children and would suggest that they hadn't got a license in children 'yet', is quite revealing. His company, GlaxoSmithKline, had documents from 1998 that showed that medication for adolescent depression failed to demonstrate any benefit for paroxetine over placebo in adolescents and demonstrated a worrying profile of adverse events for paroxetine.

I think it is fair to assume that Benbow was either lying or he didn't know that his company knew Seroxat was not beneficial to children, in fact it was quite the reverse. If the latter is true then Benbow as Head of European Psychiatry , at GlaxoSmithKline should ask himself why his employers never told him.

I got myself in to hot water when I created a video with comments from Benbow and juxtaposed them with comments from patients and the mainstream media. Apparently I had caused Benbow distress. Surely, as a consumer of their product, Seroxat, I had every right to question Benbow? Glaxo's lawyers were not happy with a comment I made regarding Benbow, I likened him to a Nazi dictator. In hindsight that was wrong, however, the question of whether Benbow lied on national TV has still not been answered.

Here is the interview with Shelley. It was conducted by John Mair and recorded in front of an audience at Coventry University.

It is an audio recording and not a video.

Right click and 'save as'

Fid


Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING

Tuesday, December 16, 2008

The Great SmithKline Cover-Up



My postman rang my bell today, he had a package for me. There I was thinking my stalker had decided to send me an early Christmas present... in fact it was better than that, so much better.

I'm about to start reading 'Side Effects: A Prosecutor, a Whistleblower, and a Bestselling Antidepressant on Trial' , a book written by Alison Bass.





From the Inside Flap
As the mental health reporter for the Boston Globe, Alison Bass's front-page reporting on conflicts of interest in medical research stunned readers, and her series on sexual misconduct among psychiatrists earned her a Pulitzer Prize nomination. Now she turns her investigative skills to a landmark case that exposed increased suicide rates among adolescents taking popular antidepressants such as Paxil, Prozac, and Zoloft.

In Side Effects we meet a courageous Ivy League university employee who risked her job to expose suspicious practices at her lab, a feisty assistant attorney general who spearheaded an unprecedented lawsuit against a pharmaceutical giant, plus the medical researchers who were being paid by the drug companies whose products they were testing. And Bass introduces us to the vulnerable children and adults placed at risk because of greed, corruption, and negligence.

Though pediatric prescriptions of Paxil—at the time one of the world's bestselling antidepressants—were soaring, there was no hard proof that the drug performed any better than sugar pills in children and adolescents. Bass reveals how data from drug trials and the suicide risk the drug posed were withheld, allowing GlaxoSmithKline, the maker of Paxil, to mislead physicians and consumers about the safety and efficacy of the drug.

When the New York State attorney general's office brought its lawsuit against GlaxoSmithKline for consumer fraud, it launched a tidal wave of protest. As a result of this case, drug companies agreed to publish negative results from their research studies. A congressional investigation into industry practices finally prompted the FDA to mandate strict warnings for all antidepressants.

In the tradition of A Civil Action, Side Effects goes behind the scenes of the headline-making case that forced the government to start protecting its citizens. It lays bare the unhealthy state of our country's pharmaceutical industry.


****

Alison has placed some documents on her blog. She writes:

The first document here is from the final GlaxoSmithKline report of study 329 (publicly available on its website), which shows that a 14-year-old boy who was in the Paxil arm of the study lost control, punching pictures, breaking glass and injuring himself in November 1994. He was hospitalized and seen as suicidal by the psychiatrists treating him. Yet this patient , known as #65 in the study, was not labeled as suicidal when the study was published in the July 2001 issue of the Journal of the American Academy of Child and Adolescent Psychiatry. (The following year, Paxil became the most widely prescribed antidepressant in the U.S.).

The second document here is a memo to Brown University's Institutional Review Board from Martin Keller, chief of psychiatry at Brown and principal investigator of study 329. In the memo, Keller reports that a teenager in the Paxil study was hospitalized in September 1995 due to becoming combative and suicidal. Yet in the memo, Keller says he has labeled this patient (#106) as noncompliant instead of suicidal as a result of taking Paxil. Likewise in the published 2001 study, this teenager is labeled noncomplaint and not included in the list of adolescents withdrawn from the study as the result of adverse side effects.

The third and perhaps most mysterious
document is a memo from Keller to the IRBs at Brown and two of its affiliated hospitals, Butler and Bradley. In this January 30, 1995 memo, Keller reports that a teenage girl, patient #70 in study 329, ingested 82 Tylenol pills on January 19 and was hospitalized at St. Ann's Hospital. She was discontinued from the study at the end of January and coded as noncompliant according to another memo from Keller to Brown's IRB here. Yet according to the GlaxoSmithKline's final report, patient #70 in the same study was a 12-year-old boy enrolled in the trial on February, 22, 1995 and withdrawn on March 24 after suffering from chest pains. This patient had been randomized to the imipramine arm of study 329.

So the question remains: how did patient #70 go from being a teenage girl who overdosed on Tylenol to a 12-year-old boy with chest pains?





How indeed?



Fid




Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING

How GSK Duped Doctor's, Regulator's and the British Public

















The Paxil Papers [Source - Christopher Lane]

This Paxil Fact File, containing confidential information, was drafted and distributed by SmithKline Beecham in 1998--for internal use only.

Foreword by Paul N. Jenner, Director and Vice President of Neuroscience and Strategic Product Development

Section 1: Towards the Second Billion -- All SSRIs Are Not the Same

Section 2: New Indications: Social Anxiety Disorder / Social Phobia

Section 3: Issues Management: Managing the Discontinuation Issue.



Related Papers

"Duration of Treatment and Depression: Relapse and Recurrence Rates" (February 2001; GlaxoSmithKline Confidential--Internal Use Only).

"Paxil CR" Product Monograph (GlaxoSmithKline; November 1, 2005).

Paxil Litigation Documents (Filed Under Seal; November 11, 2007).


Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING

Saturday, December 13, 2008

ANALYSE THIS GLAXO!






Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

By Bob Fiddaman

ISBN: 978-1-84991-120-7
CHIPMUNKA PUBLISHING

AVAILABLE FOR DOWNLOAD HERE


PAPERBACK COMING SOON












Glaxo accusing Lilly and Pfizer of marketing ploys?







Tell me now, because my memory is quite distorted but didn't GSK first tout Seroxat as a drug to cure shyness?


The words, pot, kettle and black spring to mind.


It's like one big game for the boys isn't it. It seems the main objective in this particular paper is to slag off Lilly and Pfizer.


The 'discontinuation syndrome' issue is downplayed time and time again in this file, rather than see this as an issue, it seems, GSK, then SKB, would rather play 'My dick is bigger than your dick' with Lilly and Pfizer.


Then we have this utter nonsense:






Discontinuation symptoms with Seroxat tend to occur with 2-5 days and resolve within 2 weeks?


Are you kidding me?


Point 6 of this paper claims: "Discontinuation events are not a major clinical issue, but are being used as a commercial smokescreen by Lilly in an attempt to retain market share"


NO GLAXO, They are being reported by patients worldwide, this has nothing to do with competition with Lilly. If anyone is using a commercial smokescreen it is YOU with this utter garbage about Seroxat discontinuation symptoms resolving themselves with 2weeks!


So, we can take it from this particular file that your reps went on the road and told doctors over dinner [dine & dash] that Seroxat was the dogs bollocks.


You knew there were discontinuation problems with Seroxat but you played them down by accusing Lilly of using a commercial smokescreen. Was that how the conversations went with your reps and doctors?


Face it Glaxo, you hoodwinked a nation, you hoodwinked my doctor, you put me through a personal hell regarding withdrawal, you also put these people through a personal hell, all because you were playing the 'big dick' game with Lilly and Pfizer.


I understand that SKB/GSK was/is a business and all businesses prime goal is to make money. Where YOU have messed up here Glaxo is by promoting and marketing a drug that has caused needless suffering. What is even more shameful is that you have sat on this information for years, meantime, patients have gone to their doctors, complained of zaps, aggression, intolerance to loud noises, suicidal thoughts, homicidal thoughts and a whole host of others. Their doctors, merely increase the dose, which in turn increases the Stirling silver for you.


You have duped the medicine regulators in the UK regarding what I like to term, the withdrawal issue on Seroxat, withdrawal as you know means dependence, dependence in turn would suggest addiction - that is the only reason you use 'Discontinuation Syndrome' isn't it Glaxo?


The game is up Glaxo. Seroxat made you an obscene amount of money, a profit of despair for hundreds of thousands of your customers. Even now, some of your customers have been free from the stranglehold of Seroxat, they still suffer. Long term use of Seroxat has never been investigated has it Glaxo? Whist you reaped the rewards we [your customers] put our faith in you. You abused that faith by turning the tables on your rivals in the Pharma sector. Your cash cow made you blind, it made you forget what medicine is all about. £££ signs drove you on, not the fact that you had manufactured a tablet to actually help people.


There are some callous people in this world, in my opinion, there are none more callous than you. Ruining people's lives and denying that you had any part in it is a despicable act, putting the onus on doctors to cover your own ass is pretty shameful too. I hope Andrew Witty reads this, I hope JP Garnier spends his retirement money [money the consumers gave him] without a conscience.


We may be the small people Glaxo, we may be David and you our Goliath but slowly and surely we are knocking down the walls of suppression, slowly but surely we are winning over the medicine regulators.


Our day will come Glaxo and the day I see you hang your heads in shame will be the day I stop writing about your unethical practices.


Fid



Friday, December 12, 2008

How GSK Spun Seroxat

Revealed: secret plan to push happy pills

Source: The Observer

Britain's largest drug company drew up a secret plan to double sales of the controversial anti-depressant Seroxat by marketing it as a cure for a raft of less serious mental conditions, The Observer can reveal today.

The contents of the 250-page document have alarmed health campaigners who accuse the firm, GlaxoSmithKline (GSK), of putting profit before the therapeutic needs of patients by attempting to broaden the market for the drug which has been linked to a spate of suicides.

The revelation is likely to prompt further concerns about the role and influence of the pharmaceutical industry, which has come under severe scrutiny in recent months. The document is now being investigated by a parliamentary inquiry into the drugs industry. The internal report carries a section which outlines how GSK planned to double sales of 'selective serotonin reuptake inhibitors (SSRI)' - the industry term for anti-depressants - by winning the marketing war against Seroxat's chief rival, Prozac, manufacured by Eli Lilly.

Written in 1998 and subsequently updated in following years, the section is entitled: 'Towards the second billion - all SSRIs are not the same' and discusses strategies to see off the threat posed by Prozac.

The document outlined how GSK intended to market Seroxat for a range of conditions other than clinical depression. Chief among these was a condition the company identified as social anxiety disorder, although other forms of anxiety were also discussed internally.

'What this document makes clear is that a number of different forms of anxiety were being targeted in a systematic way. The thrust was to move sales beyond the $1 billion to $2 billion mark by pushing it to people who were not clinically depressed,' said Professor David Healy, a psycho-pharmacologist at Cardiff University, who has given evidence to the House of Commons Health Select Committee.

Richard Brook, chief executive of Mind, the mental health charity which submitted the document to the committee, told the MPs it was 'all about developing new conditions for that drug and demolishing the arguments of other competitors about why their drug was not any good'.

In addition the document shows GSK made a great virtue of the fact that Seroxat had a relatively short 'half-life' compared with Prozac, an argument which has subsequently proven deeply controversial.

A half-life is the scientific term for how long it takes for the concentration of a drug to drop by 50 per cent in a patient's bloodstream. The company suggested Seroxat's short half-life meant patients could come on and off the drug easily, compared with those on Prozac, even to the extent that they could take 'treatment holidays'. 'There was an argument that a short half life was really good news,' Brook said.

'But five years later, Seroxat has withdrawal issues. It's the short half life that causes the problems. The substances get into the body so quickly it causes some sort of dependency reaction. So one of the things the company was saying was a benefit was actually a problem.'

In its submission to the parliamentary committee Mind said the original trial data submitted to the UK regulators by GSK showed the claim was at best 'naive and at worst seriously misleading'. It added that 'the Seroxat file is highly illustrative of using marketing information as facts'.

Concerns about the addictive properties of Seroxat saw the government ban its prescription to people under the age of 18 last year. This followed a review which found children taking it were more likely to self-harm or commit suicide.

A spokesman for GSK said Seroxat could be marketed at new conditions only after stringent testing. 'Medical authorities around the world have required that GSK study each condition separately in order to prove benefit in each condition specifically.'

Coming Soon to this blog - Some of the above files




Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

By Bob Fiddaman

ISBN: 978-1-84991-120-7
CHIPMUNKA PUBLISHING

AVAILABLE FOR DOWNLOAD HERE


PAPERBACK COMING SOON


Please contact me if you would like a guest post considered for publication on my blog.